AB-CHMINACA is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor (Ki=0.78nM) and CB2 receptor (Ki=0.45nM) and fully substitutes for Δ9-THC in rat discrimination studies, while being 16x more potent.[3][4] Continuing the trend seen in other cannabinoids of this generation, such as AB-FUBINACA and AB-PINACA, it contains a valine amino acid amide residue as part of its structure, where older cannabinoids contained a naphthyl or adamantane residue.
Side effects
There have been a number of reported cases of seizures, deaths, and psychotic episodes in relation to this synthetic cannabinoid.[5][6][7][8][9][10][11]
Legal status
In 2015, AB-CHMINACA became a Schedule I controlled substance in the United States.[12]
AB-CHMINACA is an Anlage II controlled substance in Germany as of May 2015.[13]
As of October 2015 AB-CHMINACA is a controlled substance in China.[14]
AB-CHMINACA is illegal in Switzerland as of December 2015.[15]
AB-CHMINACA is an illegal substance in Russian Federation.
↑Trecki J, Gerona RR, Schwartz MD (July 2015). "Synthetic Cannabinoid-Related Illnesses and Deaths". The New England Journal of Medicine. 373 (2): 103–7. doi:10.1056/NEJMp1505328. PMID26154784.
↑Klavž J, Gorenjak M, Marinšek M (August 2016). "Suicide attempt with a mix of synthetic cannabinoids and synthetic cathinones: Case report of non-fatal intoxication with AB-CHMINACA, AB-FUBINACA, alpha-PHP, alpha-PVP and 4-CMC". Forensic Science International. 265: 121–4. doi:10.1016/j.forsciint.2016.01.018. PMID26890319.
↑"关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.
